Physiology of GIP(1-30)NH2 in Humans (GA-11)

University Hospital, Gentofte, Copenhagen

Status

Completed

Conditions

Glucose Metabolism Disorders

Treatments

Other: Saline

Other: GIP(1-30)NH2

Other: GIP(1-42)

Study type

Interventional

Funder types

Other

Identifiers

NCT04792762

H-17039726

Details and patient eligibility

About

Glucose-dependent insulinotropic polypeptide (GIP) is a gut-derived incretin hormone that affects glucose, lipid and bone metabolism. Secretion of GIP into the blood stream from enteroendocrine cells is stimulated bu nutrients in the gut lumen and results in potentiation of glucose stimulated insulin secretion from the pancreas. The objective of this study is to investigate the physiology of GIP(1-30)NH2 in humans with insulin secretion as the primary endpoint. Furthermore the effects on on plasma/serum levels of glucagon, C-peptide, glucose, bone markers (CTX and P1NP) will be measured.

Enrollment

9 patients

Sex

Male

Ages

20 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy men of Northern European descent
BMI: 19-25 kg/m2
Stable body weight (±5%) in the last three months

Exclusion criteria

Treatment with medication or dietary supplements that cannot be paused for 12 hours
More than 14 units of alcohol per week or abuse of narcotics
Established liver disease and/or plasma alanine aminotransferase (ALT) ≥3 × normal value and/or INR outside the normal range
Renal impairment (eGFR <60 ml/min/1.73 m2)
Severe arteriosclerotic heart disease or severe heart failure (NYHA group III or IV)
Low blood count (haemoglobin <8.3 mol/l)
Special diet or planned body weight change before the trial period
First-degree relatives with diabetes
Participation in other clinical experiments with medication
Any disease/condition that the investigators estimate disturbing for the participation in the experiment